This is definitely a plus... no spin required.
We all knew John Stewart was a figurehead only. They always brushed aside questions about his day to day duties and always said he "oversaw" this and that. Now they finally made it official. He will still oversee the division and lend his experience and industry clout when and where needed. Nothing has changed, but his title.
It is a very GOOD thing that they are bringing in someone who will devote more time and passion to the day to day operations. This is just what we need:
An accomplished pharmaceutical industry executive, Mr. Kreppner will bring 20 years of research and development, regulatory affairs and senior management expertise to Emblem’s Medical Division. Prior to joining Emblem, Mr. Kreppner was President and Chief Operating Officer at Concordia International Corporation where he oversaw triple-digit growth of both revenue and EBITDA. He also served as Vice President, Technical Operations at Trimel Pharmaceuticals, and held various senior roles in technical operations and regulatory affairs at Biovail Corporation.
Finally Emblem will actually move towards these things:
In accepting his appointment, Mr. Kreppner said: “There is an incredible opportunity to further develop the role of cannabis and cannabinoids in medical treatment. The goal at Emblem is to identify innovative ways to bring pharmaceutical formulations of cannabis to patients, supported by clinical evidence. I am honoured to join Emblem’s medical team and look forward to contributing to the company’s success.”
No knock on Stewart. Emblem Medical just didn't become what many had envisioned. We should be at the forefront of clinical trials. We need to become the type of company that a pharmaceutical company and not another cannabis company wants to acquire.
Very excited to see this new focus and some fresh talent to implement it!
News 
Market Data 
Discover 
